Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Japanese patients with advanced solid tumors
NCT03497429Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in solid tumor (advanced stage) (2 cohorts), sponsored by Takeda. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Number of Participants With Treatment-emergent Adverse Events and 3 more. Started Apr 2018; status: completed.
02
Drugs
niraparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03497429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497429.